Clipping of news on Brazilian Culture, Law and Citizenship
 


Health

dengue vaccine has defined price

07/26/2016

This article was translated by an automatic translation system, and was therefore not reviewed by people.

 

 

transparent image

 

Dengue vaccine in Brazil will have the price ceiling varying between R $ 132.76 and R $ 138.53. The value was set by Cav on Monday (25/7).

By: Ascom

 

Dengue vaccine dose in Brazil, produced by Sanofi-Aventis Pharma Ltda., Will cost between R$ 132.76 and R$ 138.53. This is the ceiling of the variation of the "Price Factory" (PF), with which the product can be marketed in different rates of VAT in force in Brazil.

Sanofi-Aventis is to date the only company in the country with record of a dengue vaccine, called Dengvaxia®. Treatment with the vaccine includes three doses six months apart. Other vaccines for the prevention of dengue are still being analyzed by Anvisa, so they can be marketed in Brazil safely and effectively.

Check the Price Factory (PF) that may be charged by the dengue vaccine, according to the ICMS of each state:

17% (other states) R$ 132.76

17.5% (RO) R$ 133.69

18% (AM, AP, BA, MA, MG, PB, PE, PR, RN, RS, SE, SP and TO) R$ 134.63

20% (RJ) R$ 138.53 

As the price of the vaccine is defined

The value of the dengue vaccine was defined by the Executive Technical Committee on Drug Market Regulation Chamber (CMED), which is the Brazilian authority for the regulation of drug prices. The CMED is composed of representatives of the Ministries of Finance, Health, Justice, Development and Civil House, and Anvisa holds the Executive Secretariat function of the Board.

Resolution 2/2004 of CMED is the standard that defines the criteria for pricing of medicines in Brazil. According to the resolution, new drugs in the Brazilian market should have their prices set based on two criteria: the lowest international prices of a basket of countries listed in the standard or the cost of treatment with the drugs used for the same therapeutic indication.

The vaccine against dengue Sanofi-Aventis Pharma Ltda. brought a challenge to CMED because it is the first vaccine developed against the disease, ie, there is no alternative which can be compared. In addition, the vaccine has not been released in any of the countries whose prices are used as a reference. Thus, the pricing criteria established by Resolution CMED 2/2004 do not apply to the vaccine against dengue, which novelty demanded the discussion of a new rational pricing among members of CMED.

 

Source: Anvisa

Our news are taken in full of our partner sites. For this reason, we can not change their content even in cases of typographical errors.

This article was translated by an automatic translation system, and was therefore not reviewed by people.

Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.


  Subjects list
 
  Copyright (c) 2006-2009. JurisWay - All rights reserved.